NASDAQSMMT

Summit outlines November 14 FDA PDUFA date for ivonescimab BLA while planning HARMONi-3 PFS in 2H 2026 (NASDAQ:SMMT)

Earnings Call Insights: Summit Therapeutics (SMMT) Q2 2026

Management View

  • Robert Duggan (Co-CEO & Executive Chairman) said, “we expand our clinical development plan and prepare for commercialization in anticipation of a decision from the FDA on our BLA towards the end of this year,” and highlighted

Seeking Alpha’s Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.

Source link